MSN Laboratories, a leading global Indian pharmaceutical company, has become the first to launch the innovative JAK inhibitor molecules Tofacitinib (Tofadoz) and Upadacitinib (Upadoz) in India.
This landmark launch aims to improve accessibility and affordability of advanced therapies for patients battling autoimmune conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease, and Atopic Dermatitis. Both Tofadoz and Upadoz also carry US FDA approval, highlighting their global recognition.
MSN Laboratories has a strong legacy of making medicines affordable, having previously introduced nearly 50 first-time molecules in India. The company also holds the No. 1 position in Active Pharmaceutical Ingredient (API) US DMF filings.
"The introduction of Upadoz reflects our commitment to bringing affordable bioequivalent medications to alleviate the suffering of Indian patients," said Dr. M.S.N. Reddy, Founder and CMD, MSN Group.
Mr. Bharat Reddy, Executive Director, MSN Group, added, "Autoimmune diseases are a growing public health issue, and the cost of treatment is substantial. This launch will make treatment more accessible to Indian patients."
Also Read
